[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Diversified Healthcare Trust (NASDAQ:DHC):
[TEXT]
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) by 13.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,372 shares of the real estate investment trust’s stock after purchasing an additional 18,297 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.06% of Diversified Healthcare Trust worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackBarn Capital Partners LP lifted its holdings in shares of Diversified Healthcare Trust by 41.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 6,250,000 shares of the real estate investment trust’s stock valued at $14,375,000 after purchasing an additional 1,841,503 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Diversified Healthcare Trust by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 5,696,513 shares of the real estate investment trust’s stock valued at $13,105,000 after purchasing an additional 29,062 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Diversified Healthcare Trust by 9.6% during the 4th quarter. Northern Trust Corp now owns 2,134,083 shares of the real estate investment trust’s stock valued at $4,908,000 after purchasing an additional 187,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Diversified Healthcare Trust by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,060,326 shares of the real estate investment trust’s stock valued at $4,738,000 after purchasing an additional 89,415 shares during the last quarter. Finally, CastleKnight Management LP raised its stake in Diversified Healthcare Trust by 30.1% in the 4th quarter. CastleKnight Management LP now owns 1,845,842 shares of the real estate investment trust’s stock worth $4,245,000 after acquiring an additional 427,400 shares during the last quarter. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Get Diversified Healthcare Trust alerts:

Diversified Healthcare Trust Stock Performance

Shares of DHC stock opened at $3.64 on Thursday. The firm has a market capitalization of $878.73 million, a price-to-earnings ratio of -3.06 and a beta of 2.52. The company has a debt-to-equity ratio of 1.42, a current ratio of 6.35 and a quick ratio of 6.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $2.93. Diversified Healthcare Trust has a 1 year low of $2.00 and a 1 year high of $4.24.

Diversified Healthcare Trust Dividend Announcement

Diversified Healthcare Trust ( NASDAQ:DHC Get Free Report ) last issued its earnings results on Monday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $382.71 million during the quarter, compared to analyst estimates of $382.74 million. Diversified Healthcare Trust had a negative return on equity of 14.69% and a negative net margin of 18.83%.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 14th. Investors of record on Monday, July 21st will be paid a $0.01 dividend. The ex-dividend date is Monday, July 21st. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. Diversified Healthcare Trust’s dividend payout ratio (DPR) is -3.36%.

Diversified Healthcare Trust Profile

(Free Report)

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.

Further Reading

Want to see what other hedge funds are holding DHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diversified Healthcare Trust (NASDAQ:DHC – Free Report).

Receive News & Ratings for Diversified Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diversified Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/14/mitsubishi-ufj-asset-management-co-ltd-boosts-stake-in-diversified-healthcare-trust-nasdaqdhc/


[TITLE]abrdn Healthcare Investors (NYSE:HQH) Shares Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers increased its stake in abrdn Healthcare Investors (NYSE:HQH – Free Report) by 14.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 53,638 shares of the financial services provider’s stock after buying an additional 6,943 shares during the period. Cetera Investment Advisers’ holdings in abrdn Healthcare Investors were worth $871,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Nexus Investment Management ULC acquired a new position in abrdn Healthcare Investors during the first quarter valued at approximately $64,000. CoreCap Advisors LLC raised its stake in shares of abrdn Healthcare Investors by 175.8% during the fourth quarter. CoreCap Advisors LLC now owns 7,262 shares of the financial services provider’s stock valued at $117,000 after purchasing an additional 4,629 shares during the period. Comerica Bank raised its stake in shares of abrdn Healthcare Investors by 17.3% during the fourth quarter. Comerica Bank now owns 7,504 shares of the financial services provider’s stock valued at $120,000 after purchasing an additional 1,105 shares during the period. Elequin Capital LP purchased a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at approximately $121,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of abrdn Healthcare Investors during the first quarter valued at approximately $189,000. 32.60% of the stock is owned by institutional investors and hedge funds.

Get abrdn Healthcare Investors alerts:

abrdn Healthcare Investors Trading Up 1.5%

HQH opened at $16.14 on Thursday. The firm’s 50 day moving average is $15.73 and its 200-day moving average is $16.12. abrdn Healthcare Investors has a 52-week low of $13.77 and a 52-week high of $19.79.

abrdn Healthcare Investors Cuts Dividend
[Source link]: https://www.etfdailynews.com/2025/08/14/abrdn-healthcare-investors-nysehqh-shares-acquired-by-cetera-investment-advisers/


[TITLE]Atria Wealth Solutions Inc. Boosts Stake in American Healthcare REIT, Inc. (NYSE:AHR):
[TEXT]
Atria Wealth Solutions Inc. lifted its holdings in shares of American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 12.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 22,766 shares of the company’s stock after buying an additional 2,602 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in American Healthcare REIT were worth $693,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wolff Wiese Magana LLC bought a new position in shares of American Healthcare REIT during the 1st quarter valued at $25,000. MassMutual Private Wealth & Trust FSB grew its holdings in shares of American Healthcare REIT by 189.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 968 shares of the company’s stock valued at $29,000 after purchasing an additional 633 shares during the last quarter. Spirit of America Management Corp NY bought a new position in shares of American Healthcare REIT during the 1st quarter valued at $30,000. Avalon Trust Co bought a new position in shares of American Healthcare REIT during the 1st quarter valued at $36,000. Finally, Continuum Advisory LLC bought a new position in shares of American Healthcare REIT during the 1st quarter valued at $37,000. Institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Scotiabank assumed coverage on shares of American Healthcare REIT in a report on Monday, June 30th. They set a “sector outperform” rating and a $42.00 target price on the stock. Baird R W raised shares of American Healthcare REIT to a “strong-buy” rating in a report on Thursday, July 17th. Robert W. Baird assumed coverage on shares of American Healthcare REIT in a report on Friday, July 18th. They issued an “outperform” rating and a $41.00 price target on the stock. Morgan Stanley raised their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the stock an “overweight” rating in a report on Tuesday, May 20th. Finally, Truist Financial raised their price target on shares of American Healthcare REIT from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, June 9th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $39.22.

American Healthcare REIT Price Performance

Shares of American Healthcare REIT stock opened at $40.55 on Wednesday. The company’s fifty day simple moving average is $37.10 and its two-hundred day simple moving average is $32.86. The firm has a market cap of $6.47 billion, a PE ratio of -184.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.08. The company has a quick ratio of 0.38, a current ratio of 0.48 and a debt-to-equity ratio of 0.41. American Healthcare REIT, Inc. has a 12-month low of $17.00 and a 12-month high of $41.50.

American Healthcare REIT (NYSE:AHR – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.02. The firm had revenue of $542.50 million for the quarter, compared to analyst estimates of $539.49 million. American Healthcare REIT had a negative net margin of 1.56% and a negative return on equity of 1.43%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 EPS. As a group, equities analysts expect that American Healthcare REIT, Inc. will post 1.41 EPS for the current year.

American Healthcare REIT Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 18th. Stockholders of record on Monday, June 30th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.5%. American Healthcare REIT’s payout ratio is presently -454.55%.

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of American Healthcare REIT stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $36.10, for a total transaction of $139,346.00. Following the sale, the executive owned 95,671 shares of the company’s stock, valued at approximately $3,453,723.10. The trade was a 3.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.00% of the company’s stock.

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/13/atria-wealth-solutions-inc-boosts-stake-in-american-healthcare-reit-inc-nyseahr/

================================================================================

[TITLE]Charles Schwab Investment Management Inc. Acquires 89,926 Shares of American Healthcare REIT, Inc. (NYSE:AHR):
[TEXT]
Charles Schwab Investment Management Inc. lifted its holdings in American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 4.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,235,051 shares of the company’s stock after buying an additional 89,926 shares during the period. Charles Schwab Investment Management Inc.’s holdings in American Healthcare REIT were worth $67,722,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in AHR. Vanguard Group Inc. grew its holdings in American Healthcare REIT by 22.4% during the 1st quarter. Vanguard Group Inc. now owns 18,795,192 shares of the company’s stock valued at $569,494,000 after purchasing an additional 3,437,861 shares during the last quarter. Northern Trust Corp boosted its position in shares of American Healthcare REIT by 99.0% during the fourth quarter. Northern Trust Corp now owns 1,732,882 shares of the company’s stock valued at $49,249,000 after buying an additional 861,882 shares during the period. Waterfront Capital Partners LLC purchased a new position in shares of American Healthcare REIT during the fourth quarter valued at approximately $15,066,000. Adage Capital Partners GP L.L.C. boosted its position in shares of American Healthcare REIT by 115.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 925,000 shares of the company’s stock valued at $26,288,000 after buying an additional 495,000 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of American Healthcare REIT during the first quarter valued at approximately $13,384,000. 16.68% of the stock is currently owned by institutional investors.

Get American Healthcare REIT alerts:

Insider Buying and Selling

In related news, CIO Stefan K.L. Oh sold 3,860 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $36.10, for a total transaction of $139,346.00. Following the completion of the sale, the executive owned 95,671 shares of the company’s stock, valued at $3,453,723.10. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.92% of the stock is owned by insiders.

American Healthcare REIT Price Performance

Shares of AHR opened at $40.43 on Friday. The company has a 50 day moving average price of $37.33 and a 200-day moving average price of $32.99. American Healthcare REIT, Inc. has a fifty-two week low of $18.01 and a fifty-two week high of $41.50. The stock has a market capitalization of $6.45 billion, a PE ratio of -183.77, a PEG ratio of 2.26 and a beta of 1.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.38 and a current ratio of 0.48.

American Healthcare REIT (NYSE:AHR – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.02. American Healthcare REIT had a negative net margin of 1.56% and a negative return on equity of 1.43%. The firm had revenue of $542.50 million during the quarter, compared to analysts’ expectations of $539.49 million. During the same quarter in the prior year, the company earned $0.33 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Equities analysts predict that American Healthcare REIT, Inc. will post 1.41 earnings per share for the current fiscal year.

American Healthcare REIT Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 18th. Investors of record on Monday, June 30th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a yield of 2.5%. American Healthcare REIT’s dividend payout ratio is presently -454.55%.

Analysts Set New Price Targets

Several brokerages have issued reports on AHR. Truist Financial boosted their target price on American Healthcare REIT from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, June 9th. Baird R W upgraded American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. JMP Securities upped their target price on shares of American Healthcare REIT from $40.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Monday. Royal Bank Of Canada set a $45.00 target price on shares of American Healthcare REIT and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Morgan Stanley upped their target price on shares of American Healthcare REIT from $37.00 to $45.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 20th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $40.44.

View Our Latest Stock Analysis on AHR

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/15/charles-schwab-investment-management-inc-acquires-89926-shares-of-american-healthcare-reit-inc-nyseahr/


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Diversified Healthcare Trust (NASDAQ:DHC):
[TEXT]
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) by 13.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,372 shares of the real estate investment trust’s stock after purchasing an additional 18,297 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.06% of Diversified Healthcare Trust worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackBarn Capital Partners LP lifted its holdings in shares of Diversified Healthcare Trust by 41.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 6,250,000 shares of the real estate investment trust’s stock valued at $14,375,000 after purchasing an additional 1,841,503 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Diversified Healthcare Trust by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 5,696,513 shares of the real estate investment trust’s stock valued at $13,105,000 after purchasing an additional 29,062 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Diversified Healthcare Trust by 9.6% during the 4th quarter. Northern Trust Corp now owns 2,134,083 shares of the real estate investment trust’s stock valued at $4,908,000 after purchasing an additional 187,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Diversified Healthcare Trust by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,060,326 shares of the real estate investment trust’s stock valued at $4,738,000 after purchasing an additional 89,415 shares during the last quarter. Finally, CastleKnight Management LP raised its stake in Diversified Healthcare Trust by 30.1% in the 4th quarter. CastleKnight Management LP now owns 1,845,842 shares of the real estate investment trust’s stock worth $4,245,000 after acquiring an additional 427,400 shares during the last quarter. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Get Diversified Healthcare Trust alerts:

Diversified Healthcare Trust Stock Performance

Shares of DHC stock opened at $3.64 on Thursday. The firm has a market capitalization of $878.73 million, a price-to-earnings ratio of -3.06 and a beta of 2.52. The company has a debt-to-equity ratio of 1.42, a current ratio of 6.35 and a quick ratio of 6.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $2.93. Diversified Healthcare Trust has a 1 year low of $2.00 and a 1 year high of $4.24.

Diversified Healthcare Trust Dividend Announcement

Diversified Healthcare Trust ( NASDAQ:DHC Get Free Report ) last issued its earnings results on Monday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $382.71 million during the quarter, compared to analyst estimates of $382.74 million. Diversified Healthcare Trust had a negative return on equity of 14.69% and a negative net margin of 18.83%.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 14th. Investors of record on Monday, July 21st will be paid a $0.01 dividend. The ex-dividend date is Monday, July 21st. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. Diversified Healthcare Trust’s dividend payout ratio (DPR) is -3.36%.

Diversified Healthcare Trust Profile

(Free Report)

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.

Further Reading

Want to see what other hedge funds are holding DHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diversified Healthcare Trust (NASDAQ:DHC – Free Report).

Receive News & Ratings for Diversified Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diversified Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/14/mitsubishi-ufj-asset-management-co-ltd-boosts-stake-in-diversified-healthcare-trust-nasdaqdhc/


[TITLE]abrdn Healthcare Investors (NYSE:HQH) Shares Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers increased its stake in abrdn Healthcare Investors (NYSE:HQH – Free Report) by 14.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 53,638 shares of the financial services provider’s stock after buying an additional 6,943 shares during the period. Cetera Investment Advisers’ holdings in abrdn Healthcare Investors were worth $871,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Nexus Investment Management ULC acquired a new position in abrdn Healthcare Investors during the first quarter valued at approximately $64,000. CoreCap Advisors LLC raised its stake in shares of abrdn Healthcare Investors by 175.8% during the fourth quarter. CoreCap Advisors LLC now owns 7,262 shares of the financial services provider’s stock valued at $117,000 after purchasing an additional 4,629 shares during the period. Comerica Bank raised its stake in shares of abrdn Healthcare Investors by 17.3% during the fourth quarter. Comerica Bank now owns 7,504 shares of the financial services provider’s stock valued at $120,000 after purchasing an additional 1,105 shares during the period. Elequin Capital LP purchased a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at approximately $121,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of abrdn Healthcare Investors during the first quarter valued at approximately $189,000. 32.60% of the stock is owned by institutional investors and hedge funds.

Get abrdn Healthcare Investors alerts:

abrdn Healthcare Investors Trading Up 1.5%

HQH opened at $16.14 on Thursday. The firm’s 50 day moving average is $15.73 and its 200-day moving average is $16.12. abrdn Healthcare Investors has a 52-week low of $13.77 and a 52-week high of $19.79.

abrdn Healthcare Investors Cuts Dividend
[Source link]: https://www.etfdailynews.com/2025/08/14/abrdn-healthcare-investors-nysehqh-shares-acquired-by-cetera-investment-advisers/

================================================================================

[TITLE]Deutsche Bank AG Has $12.63 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD):
[TEXT]
Deutsche Bank AG trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 760,594 shares of the biopharmaceutical company’s stock after selling 281,853 shares during the period. Deutsche Bank AG owned
[Source link]: https://www.etfdailynews.com/2025/08/15/deutsche-bank-ag-has-12-63-million-stake-in-acadia-pharmaceuticals-inc-nasdaqacad/


[TITLE]XTX Topco Ltd Invests $110,000 in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA):
[TEXT]
XTX Topco Ltd purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 19,941 shares of the biotechnology company’s stock, valued at approximately $110,000.

Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 2,274 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth approximately $40,000. Squarepoint Ops LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $66,000. Velan Capital Investment Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $75,000. Finally, Corton Capital Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth approximately $77,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals Trading Up 2.1%

Shares of ENTA stock opened at $7.74 on Friday. The stock has a market capitalization of $165.48 million, a P/E ratio of -1.79 and a beta of 0.88. The firm’s 50 day moving average is $7.39 and its 200 day moving average is $6.46. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $13.43.

Analyst Upgrades and Downgrades

Enanta Pharmaceuticals ( NASDAQ:ENTA Get Free Report ) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The company had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $16.21 million. On average, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday. Finally, HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a research note on Monday, July 28th. They set a “buy” rating and a $20.00 price target on the stock.

Read Our Latest Stock Report on ENTA

Enanta Pharmaceuticals Company Profile

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Stories

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/15/xtx-topco-ltd-invests-110000-in-enanta-pharmaceuticals-inc-nasdaqenta/


[TITLE]Vanguard Group Inc. Has $747.06 Million Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ):
[TEXT]
Vanguard Group Inc. trimmed its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 0.3% in the first quarter, Holdings Channel reports. The institutional investor owned 6,017,403 shares of the specialty pharmaceutical company’s stock after selling 18,780 shares during the period. Vanguard Group Inc. owned approximately 0.10% of Jazz Pharmaceuticals worth $747,061,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hurley Capital LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the last quarter. Parallel Advisors LLC increased its stake in Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 119 shares during the last quarter. Picton Mahoney Asset Management grew its stake in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 269 shares during the last quarter. Finally, Spire Wealth Management grew its stake in shares of Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 161 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Get Jazz Pharmaceuticals alerts:

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Royal Bank Of Canada decreased their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.43.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $113.33 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market cap of $6.87 billion, a price-to-earnings ratio of -16.84, a P/E/G ratio of 7.12 and a beta of 0.34. The company’s fifty day moving average is $111.38 and its 200 day moving average is $117.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.30 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

See Also

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/13/vanguard-group-inc-has-747-06-million-stake-in-jazz-pharmaceuticals-plc-nasdaqjazz/


[TITLE]Cetera Investment Advisers Purchases 444 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ):
[TEXT]
Cetera Investment Advisers increased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 4.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,536 shares of the specialty pharmaceutical company’s stock after purchasing an additional 444 shares during the quarter. Cetera Investment Advisers’ holdings in Jazz Pharmaceuticals were worth $1,308,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Burney Co. raised its holdings in shares of Jazz Pharmaceuticals by 7.0% in the 1st quarter. Burney Co. now owns 25,512 shares of the specialty pharmaceutical company’s stock valued at $3,167,000 after purchasing an additional 1,672 shares during the period. Convergence Investment Partners LLC raised its position in shares of Jazz Pharmaceuticals by 24.4% in the first quarter. Convergence Investment Partners LLC now owns 10,428 shares of the specialty pharmaceutical company’s stock valued at $1,295,000 after purchasing an additional 2,043 shares during the period. Readystate Asset Management LP raised its position in shares of Jazz Pharmaceuticals by 7.7% in the first quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 1,635 shares during the period. KLP Kapitalforvaltning AS raised its position in shares of Jazz Pharmaceuticals by 1.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock valued at $2,148,000 after purchasing an additional 300 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Jazz Pharmaceuticals in the first quarter valued at about $10,900,000. 89.14% of the stock is owned by institutional investors.

Get Jazz Pharmaceuticals alerts:

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares of the company’s stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $111.30 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The firm has a market cap of $6.75 billion, a P/E ratio of -16.54, a P/E/G ratio of 5.15 and a beta of 0.34. The company’s 50-day moving average price is $111.27 and its two-hundred day moving average price is $117.47.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JAZZ. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Piper Sandler reissued an “overweight” rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Royal Bank Of Canada dropped their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Finally, Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $181.43.

Check Out Our Latest Stock Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/11/cetera-investment-advisers-purchases-444-shares-of-jazz-pharmaceuticals-plc-nasdaqjazz/

================================================================================

[TITLE]Freeze-Thaw Bags Market Trends and Investment Opportunities to 2030 - Biotechnology and Food Storage Applications Lead the Industry:
[TEXT]
Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Freeze-Thaw Bags
[Source link]: https://www.globenewswire.com/news-release/2025/08/14/3133624/28124/en/Freeze-Thaw-Bags-Market-Trends-and-Investment-Opportunities-to-2030-Biotechnology-and-Food-Storage-Applications-Lead-the-Industry.html


[TITLE]Cetera Investment Advisers Has $1.34 Million Holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE):
[TEXT]
Cetera Investment Advisers cut its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 8.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,118 shares of the company’s stock after selling 1,992 shares during the quarter. Cetera Investment Advisers’ holdings in Invesco Biotechnology & Genome ETF were worth $1,340,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PBE. JPMorgan Chase & Co. raised its position in shares of Invesco Biotechnology & Genome ETF by 30.0% during the fourth quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock worth $43,000 after purchasing an additional 150 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 10.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,066 shares of the company’s stock worth $271,000 after purchasing an additional 390 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 12.5% during the first quarter. Janney Montgomery Scott LLC now owns 5,424 shares of the company’s stock worth $344,000 after purchasing an additional 604 shares during the period. Capital Analysts LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 55.9% during the fourth quarter. Capital Analysts LLC now owns 1,715 shares of the company’s stock worth $114,000 after purchasing an additional 615 shares during the period. Finally, Millstone Evans Group LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 75.8% during the first quarter. Millstone Evans Group LLC now owns 1,684 shares of the company’s stock worth $107,000 after purchasing an additional 726 shares during the period.

Get Invesco Biotechnology & Genome ETF alerts:

Invesco Biotechnology & Genome ETF Stock Down 0.0%

Shares of NYSEARCA:PBE opened at $64.94 on Monday. Invesco Biotechnology & Genome ETF has a twelve month low of $54.52 and a twelve month high of $72.84. The stock’s 50 day moving average is $65.09 and its 200-day moving average is $64.31. The firm has a market capitalization of $224.04 million, a price-to-earnings ratio of 20.44 and a beta of 0.87.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.

See Also

Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).

Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/11/cetera-investment-advisers-has-1-34-million-holdings-in-invesco-biotechnology-genome-etf-nysearcapbe/

================================================================================

[TITLE]Applied AI in Healthcare Market 2025-2029: Key Investment Opportunities for Treatment & Care, Administrative & Operational Efficiency, Diagnostic, and Disease Prevention & Management Applications:
[TEXT]
Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Applied AI in Healthcare Market 2025-2029" has been added to ResearchAndMarkets.com's offering.

The applied AI in healthcare market is projected to experience significant growth, with an increase of USD 75.23 billion anticipated during 2024-2029, at an impressive CAGR of 37.3%. This robust expansion highlights the market's dynamic nature and the essential role of AI in transforming healthcare operations. The report offers an up-to-date analysis of the current market scenario, emerging trends, and growth drivers, alongside a detailed vendor analysis featuring approximately 25 vendors.

Key market growth is fueled by the proliferation of big data and the growing demand for actionable insights. These insights are vital for enhancing operational efficiency and mitigating clinician burnout. Additionally, continuous advancements in AI algorithms and computational infrastructure further propel market development.

The rise of generative AI in clinical and administrative workflows, coupled with the increase in multimodal AI for comprehensive patient analysis, are highlighted as key drivers of market growth. Additionally, the proliferation of AI at the edge for point-of-care diagnostics is expected to contribute to increased market demand.

The report integrates primary and secondary information from key industry participants, providing comprehensive market size data, regional segment analysis, and vendor landscapes, along with insights into key companies involved in the market.

The applied AI in healthcare market is segmented as follows:

By Component:

Solutions

Services

By Application:

Treatment and care

Administrative and operational efficiency

Diagnostic

Disease prevention and management

By End-user:

Hospitals and clinics

Research and academic institutes

By Geographical Landscape:

North America

Europe

APAC

South America

Middle East and Africa

The report covers the following key areas:

Applied AI In Healthcare Market sizing

Applied AI In Healthcare Market forecast

Applied AI In Healthcare Market industry analysis

A detailed vendor analysis is designed to help clients bolster their market positions. The report provides an in-depth evaluation of leading vendors including AiCure, Augmedix Inc., CloudMedx Inc., and many others. Insights on upcoming trends and challenges are included to inform strategic planning and leverage growth opportunities.

A selection of companies mentioned in this report includes, but is not limited to:

AiCure

Augmedix Inc

CloudMedx Inc.

Eko Devices Inc.

Enlitic Inc.

GE Healthcare Technologies Inc.

Google LLC

International Business Machines Corp.

Koninklijke Philips N.V.

Lunit Inc.

Medtronic PLC

Microsoft Corp.

NVIDIA Corp.

Oncora Medical Inc.

PathAI Inc.

Qventus Inc.

Siemens Healthineers AG

Tempus Labs Inc.

Verantos Inc.

XpertDox LLC
[Source link]: https://www.globenewswire.com/news-release/2025/08/15/3134326/28124/en/Applied-AI-in-Healthcare-Market-2025-2029-Key-Investment-Opportunities-for-Treatment-Care-Administrative-Operational-Efficiency-Diagnostic-and-Disease-Prevention-Management-Applica.html


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Diversified Healthcare Trust (NASDAQ:DHC):
[TEXT]
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) by 13.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,372 shares of the real estate investment trust’s stock after purchasing an additional 18,297 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.06% of Diversified Healthcare Trust worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackBarn Capital Partners LP lifted its holdings in shares of Diversified Healthcare Trust by 41.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 6,250,000 shares of the real estate investment trust’s stock valued at $14,375,000 after purchasing an additional 1,841,503 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Diversified Healthcare Trust by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 5,696,513 shares of the real estate investment trust’s stock valued at $13,105,000 after purchasing an additional 29,062 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Diversified Healthcare Trust by 9.6% during the 4th quarter. Northern Trust Corp now owns 2,134,083 shares of the real estate investment trust’s stock valued at $4,908,000 after purchasing an additional 187,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Diversified Healthcare Trust by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,060,326 shares of the real estate investment trust’s stock valued at $4,738,000 after purchasing an additional 89,415 shares during the last quarter. Finally, CastleKnight Management LP raised its stake in Diversified Healthcare Trust by 30.1% in the 4th quarter. CastleKnight Management LP now owns 1,845,842 shares of the real estate investment trust’s stock worth $4,245,000 after acquiring an additional 427,400 shares during the last quarter. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Get Diversified Healthcare Trust alerts:

Diversified Healthcare Trust Stock Performance

Shares of DHC stock opened at $3.64 on Thursday. The firm has a market capitalization of $878.73 million, a price-to-earnings ratio of -3.06 and a beta of 2.52. The company has a debt-to-equity ratio of 1.42, a current ratio of 6.35 and a quick ratio of 6.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $2.93. Diversified Healthcare Trust has a 1 year low of $2.00 and a 1 year high of $4.24.

Diversified Healthcare Trust Dividend Announcement

Diversified Healthcare Trust ( NASDAQ:DHC Get Free Report ) last issued its earnings results on Monday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $382.71 million during the quarter, compared to analyst estimates of $382.74 million. Diversified Healthcare Trust had a negative return on equity of 14.69% and a negative net margin of 18.83%.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 14th. Investors of record on Monday, July 21st will be paid a $0.01 dividend. The ex-dividend date is Monday, July 21st. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. Diversified Healthcare Trust’s dividend payout ratio (DPR) is -3.36%.

Diversified Healthcare Trust Profile

(Free Report)

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.

Further Reading

Want to see what other hedge funds are holding DHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diversified Healthcare Trust (NASDAQ:DHC – Free Report).

Receive News & Ratings for Diversified Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diversified Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/14/mitsubishi-ufj-asset-management-co-ltd-boosts-stake-in-diversified-healthcare-trust-nasdaqdhc/


[TITLE]abrdn Healthcare Investors (NYSE:HQH) Shares Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers increased its stake in abrdn Healthcare Investors (NYSE:HQH – Free Report) by 14.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 53,638 shares of the financial services provider’s stock after buying an additional 6,943 shares during the period. Cetera Investment Advisers’ holdings in abrdn Healthcare Investors were worth $871,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Nexus Investment Management ULC acquired a new position in abrdn Healthcare Investors during the first quarter valued at approximately $64,000. CoreCap Advisors LLC raised its stake in shares of abrdn Healthcare Investors by 175.8% during the fourth quarter. CoreCap Advisors LLC now owns 7,262 shares of the financial services provider’s stock valued at $117,000 after purchasing an additional 4,629 shares during the period. Comerica Bank raised its stake in shares of abrdn Healthcare Investors by 17.3% during the fourth quarter. Comerica Bank now owns 7,504 shares of the financial services provider’s stock valued at $120,000 after purchasing an additional 1,105 shares during the period. Elequin Capital LP purchased a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at approximately $121,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of abrdn Healthcare Investors during the first quarter valued at approximately $189,000. 32.60% of the stock is owned by institutional investors and hedge funds.

Get abrdn Healthcare Investors alerts:

abrdn Healthcare Investors Trading Up 1.5%

HQH opened at $16.14 on Thursday. The firm’s 50 day moving average is $15.73 and its 200-day moving average is $16.12. abrdn Healthcare Investors has a 52-week low of $13.77 and a 52-week high of $19.79.

abrdn Healthcare Investors Cuts Dividend
[Source link]: https://www.etfdailynews.com/2025/08/14/abrdn-healthcare-investors-nysehqh-shares-acquired-by-cetera-investment-advisers/

================================================================================

